FDA announced plans to revise previously issued draft guidance concerning pre-submission of facility information in ANDAs. The revisions will be intended to accommodate the new generic drug user fee (GDUFA II) provisions of the generic drug user fee in the FDA Reauthorization Act of 2017 (FDARA) and to establish policies necessary for expedited review of priority submissions.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
